about
Surgical implantation of adipose tissue reverses diabetes in lipoatrophic miceIdentification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobeFunctional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetesEndogenous glucose production is inhibited by the adipose-derived protein Acrp30Hypothalamic inhibition of acetyl-CoA carboxylase stimulates hepatic counter-regulatory response independent of AMPK activation in ratsExpression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinedionesMCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesityLocal and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaBMyostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity.Anti-obesity activity of diglyceride containing conjugated linoleic acid in C57BL/6J ob/ob mice.Thiazolidinediones: a new class of antidiabetic drugs.Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.Alternative Gnas gene products have opposite effects on glucose and lipid metabolism.Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient miceLoss of stearoyl-CoA desaturase-1 function protects mice against adiposityTreatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonistsAdverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.Enhancing insulin action: from chemical elements to thiazolidinediones.PPAR gamma and human metabolic diseaseInhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice.Novel insulin sensitizers: pharmacogenomic aspects.Thiazolidinediones in the treatment of type 2 diabetes.PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?Revisiting PPARγ as a target for the treatment of metabolic disordersLiver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.Biology and toxicology of PPARgamma ligands.Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.Lipodystrophy: pathophysiology and advances in treatmentThiazolidinediones -- some recent developments.Suppression of the C/EBP family of transcription factors in adipose tissue causes lipodystrophy.Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse.Life without white fat: a transgenic mouseInsulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophyMuscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside59th annual meeting of the American Diabetes Association. June 19-22, 1999, San Diego, CA, USA.Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations.
P2860
Q24620943-BD0D0345-58D8-4561-BBB8-F4D03EF31EF6Q28211498-E3136E09-EE9F-43A8-8BAF-111E6BD8A862Q28345343-C5F096FE-DC71-4901-ABEA-9AD3C8E9D6F1Q28366672-42EB0159-644E-472E-8B7D-C313036776D0Q28486463-BFBBA6B7-F34C-4C12-B9C3-8E9121D321AAQ28569627-AA987EEF-3B5F-4A12-9108-4531EE12BAD0Q29614283-1CC7A568-9F66-4B5A-B23C-261E6834165CQ29619314-90B1D8C7-C3BE-446B-8AC7-9F604D9B6EA8Q33419373-F559F602-DA35-4D94-9357-AF85AF5ABCC4Q33569119-7A86347F-F8A3-4C09-A03C-E41671517CB4Q33607634-FE8E4A00-7510-43B5-B05F-5BF2FB53835BQ33780711-ED03112D-7B88-42AA-A94C-1F267B80D321Q33821507-BEF40FA4-036D-4B71-883A-D975E418ABFAQ33957864-30A089AB-312B-4646-A359-0807907FEE5BQ33960868-F881087B-6934-458E-9AAE-71F23B0843FBQ34011043-478E167C-EB4B-419A-90B8-7A238DBE53F2Q34187120-404A0532-7086-4E67-BD30-BF9F76380110Q34235817-E06CAE45-BE27-4AAC-B6A4-E72388E46CE1Q34268346-744066AB-ECAE-4716-A932-40E477959CD7Q34416432-40CC3AEA-8601-43AF-B648-F9915F7143FCQ34430237-930226D7-F588-40E4-A4C8-D8EFD7641EFEQ34609164-04D32E70-9D2A-421B-AD3F-22AAD33E5A03Q34628604-1BCA2A3D-90B4-43EC-B3A3-BB21559BC87DQ34722604-A2763332-66C3-4BF2-A5C2-593D1E531FA1Q34798213-C5762105-638B-471F-AC17-D66FBFF36F4DQ34835012-4D3D334A-704D-49F9-8A49-4534F4BD6AA7Q34986544-65BCBF0B-D49E-4592-89D0-B4894D68535BQ35049153-EEF82E6C-FA77-4EB2-9E57-029D5A68DCD0Q35108391-2A4A434E-926D-4651-B82A-734C25B84AC7Q35148915-183429FF-81C4-4E7A-823C-D512AAA889CFQ35164761-2083574B-9DC8-4536-8524-2AF273B1E95FQ35173880-51BEB005-7F90-444B-ABEF-DA5F71B075D0Q35195052-DD38781B-70B9-49AE-9D1A-9C48084C5E8FQ35210661-8898AAB9-ED38-4E01-BDFF-82CC8C7DEAD8Q35210714-A18DC865-23DD-428F-9D86-9E09FB649C04Q35242884-E792CDA8-43BA-4A1F-9EA2-4F1233974CBDQ35813795-D47A4382-C1D7-410A-87DD-1D664D222743Q36056207-31F26775-49F6-4F71-88B8-F6E2DE9FF76CQ36181381-5289F9E8-62BB-4BC3-86DE-56D58B064C30Q36339534-98B4E9B8-95EC-4F03-9CD5-40FD8BB35DF8
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Troglitazone action is independent of adipose tissue
@ast
Troglitazone action is independent of adipose tissue
@en
Troglitazone action is independent of adipose tissue
@nl
type
label
Troglitazone action is independent of adipose tissue
@ast
Troglitazone action is independent of adipose tissue
@en
Troglitazone action is independent of adipose tissue
@nl
prefLabel
Troglitazone action is independent of adipose tissue
@ast
Troglitazone action is independent of adipose tissue
@en
Troglitazone action is independent of adipose tissue
@nl
P2093
P2860
P3181
P356
P1476
Troglitazone action is independent of adipose tissue
@en
P2093
C F Burant
J Lohmiller
N O Davidson
R A Graves
P2860
P304
P3181
P356
10.1172/JCI119839
P407
P577
1997-12-01T00:00:00Z